Study identification

EU PAS number

EUPAS1000000758

Study ID

1000000758

Official title and acronym

Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)

DARWIN EU® study

No

Study countries

China

Study status

Planned

Contact details

Global Development Leader Amgen Inc. medinfo@amgen.com

Study contact

Global Development Leader Amgen Inc.

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Data analysis start date

Planned:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable